Literature DB >> 9386849

Effect of antipanic treatment on response to carbon dioxide.

J M Gorman1, S T Browne, L A Papp, J Martinez, L Welkowitz, J D Coplan, R R Goetz, J Kent, D F Klein.   

Abstract

BACKGROUND: Disordered breathing among patients with panic disorder, including hyperventilation during attacks and increased anxiogenic response to carbon dioxide (CO2) inhalation, is well established. We wished to assess whether there is a change in the physiological response to CO2 after patients have undergone antipanic therapy with either tricyclic antidepressants or cognitive behavioral therapy (CBT).
METHODS: Twenty-nine patients with panic disorder underwent baseline CO2 sensitivity testing using the traditional Read rebreathing method and then received either antidepressant treatment (n = 21) or CBT (n = 8). After completing treatment, CO2 testing was repeated. A comparison sample of 14 normal volunteers also had two CO2 sensitivity tests, separated by an average of 21.6 (SD = 8.8) weeks.
RESULTS: Using a liberal standard, in which all CO2 sensitivity tests whose correlations between minute ventilation and end-tidal CO2 were at least .75 were used, patients, but not controls, demonstrated a significant reduction in CO2 sensitivity between the first and second test. Using a more conservative .90 correlation standard reduced the sample size available and resulted in trend reduction in patients but no significant change in controls. There was a suggestion that the change was most pronounced in treatment responders, although the number of patient nonresponders is extremely small in this sample.
CONCLUSIONS: These data indicate that treatment reduces CO2 sensitivity in patients with panic disorder. We speculate that manipulation of the serotonergic and noradrenergic neurotransmission systems, both known to play a role in the control of respiration, may have a specific effect in reducing respiratory hyperactivity in panic disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386849     DOI: 10.1016/s0006-3223(97)00160-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.

Authors:  Kelly A Warren; Irene C Solomon
Journal:  Respir Physiol Neurobiol       Date:  2012-07-31       Impact factor: 1.931

2.  The effect of doxapram on brain imaging in patients with panic disorder.

Authors:  Amir Garakani; Monte S Buchsbaum; Randall E Newmark; Chelain Goodman; Cindy J Aaronson; Jose M Martinez; Yuliya Torosjan; King-Wai Chu; Jack M Gorman
Journal:  Eur Neuropsychopharmacol       Date:  2007-06-08       Impact factor: 4.600

3.  Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder.

Authors:  Caroline Bell; Sean Hood; John Potokar; Jon Nash; Mariona Adrover; Chris Frampton; Dana Hince; Ann Rich; Spilios Argyropoulos; David Nutt
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

4.  Changes in respiration mediate changes in fear of bodily sensations in panic disorder.

Authors:  Alicia E Meuret; David Rosenfield; Stefan G Hofmann; Michael K Suvak; Walton T Roth
Journal:  J Psychiatr Res       Date:  2008-10-05       Impact factor: 4.791

5.  CARbon DIoxide for the treatment of Febrile seizures: rationale, feasibility, and design of the CARDIF-study.

Authors:  Stephanie Ohlraun; Tobias Wollersheim; Claudia Weiß; Peter Martus; Steffen Weber-Carstens; Dietmar Schmitz; Markus Schuelke
Journal:  J Transl Med       Date:  2013-06-27       Impact factor: 5.531

6.  Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans.

Authors:  Ameera X Patel; Sam R Miller; Pradeep J Nathan; Ponmani Kanakaraj; Antonella Napolitano; Philip Lawrence; Annelize Koch; Edward T Bullmore
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.